Expand MRK Menu
MRK MENU

MRK Latest Press Releases

-- May 1, 2024 --

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Business Wire 7:15 AM

-- April 29, 2024 --

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults Business Wire 9:00 AM

-- April 25, 2024 --

Merck Announces First-Quarter 2024 Financial Results Business Wire 6:30 AM

-- April 4, 2024 --

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer Business Wire 6:45 AM

-- April 3, 2024 --

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- April 1, 2024 --

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 Business Wire 6:45 AM

-- March 28, 2024 --

European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults Business Wire 6:45 AM

-- March 26, 2024 --

FDA Approves Merck's WINREVAIR (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) Business Wire 6:21 PM

-- March 21, 2024 --

Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth InvestorBrandMedia 7:20 PM
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Maintenance LYNPARZA (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer Business Wire 6:45 AM

-- March 19, 2024 --

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults Business Wire 9:00 AM

-- March 15, 2024 --

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform PRNewswire 4:23 PM
Merck's KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Business Wire 6:45 AM

-- March 13, 2024 --

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL9 Business Wire 3:00 AM

-- March 11, 2024 --

Merck Completes Acquisition of Harpoon Therapeutics, Inc. Business Wire 8:15 AM

-- March 6, 2024 --

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 Business Wire 10:25 AM

-- March 5, 2024 --

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments Globe Newswire 8:30 AM
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference Business Wire 6:45 AM

-- March 4, 2024 --

Merck to Participate in the Leerink Partners Global Biopharma Conference 2024 Business Wire 6:45 AM

-- February 27, 2024 --

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Business Wire 7:00 AM
Merck to Participate in the TD Cowen 44th Annual Health Care Conference Business Wire 6:45 AM

-- February 23, 2024 --

Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence Business Wire 6:20 AM

-- February 20, 2024 --

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma Business Wire 6:45 AM

-- February 15, 2024 --

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032 Globe Newswire 8:45 AM

-- February 5, 2024 --

Elanco Announces Sale of Aqua Business for $1.3 Billion PRNewswire 6:33 AM
Merck Animal Health to Acquire Elanco's Aqua Business Business Wire 6:33 AM

-- February 1, 2024 --

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results Business Wire 6:30 AM

-- January 27, 2024 --

Merck's KEYTRUDA (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy Business Wire 10:00 AM

-- January 26, 2024 --

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery Business Wire 10:00 AM

-- January 23, 2024 --

Merck Announces Second-Quarter 2024 Dividend Business Wire 2:44 PM

-- January 19, 2024 --

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1 Business Wire 6:45 AM

-- January 15, 2024 --

Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams PRNewswire 8:15 AM

-- January 12, 2024 --

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer Business Wire 5:30 PM

-- January 10, 2024 --

HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP Business Wire 5:09 PM

-- January 8, 2024 --

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline Business Wire 7:30 AM

-- January 5, 2024 --

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline Business Wire 6:45 AM

-- January 3, 2024 --

Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Business Wire 6:45 AM

-- December 22, 2023 --

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Business Wire 8:00 AM

-- December 20, 2023 --

Merck Provides U.S. Regulatory Update on Gefapixant Business Wire 4:30 PM
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference Business Wire 6:45 AM

-- December 19, 2023 --

FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults Business Wire 6:45 AM

-- December 18, 2023 --

European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS =1) and Advanced Biliary Tract Cancer Business Wire 6:45 AM

-- December 15, 2023 --

FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer Business Wire 5:00 PM

-- December 14, 2023 --

FDA Approves Merck's WELIREG (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI Business Wire 7:00 PM
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years ACCESSWIRE 6:31 AM

-- December 11, 2023 --

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer Business Wire 6:45 AM
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO (Fluralaner) for Use in Dogs Business Wire 6:45 AM

-- December 8, 2023 --

Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma Business Wire 6:45 AM

-- December 7, 2023 --

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA (pembrolizumab) Plus LYNPARZA (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility Business Wire 6:45 AM
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire 6:00 AM